Pharmacyclics' (UNKNOWN: PCYC.DL ) share price has tripled in the last 12 months, and its shares saw another 7% jump today after the company's flagship drug, Ibrutinib, was given the Breakthrough Therapy Designation from the FDA. This is also positive news for the company's partner, Johnson & Johnson, which has already paid Pharmacyclics $300 million and could give another $675 million if Ibrutinib meets its remaining milestones. In this video, health care analyst Max Macaluso discusses today's news.
Is this drug a good fit for Johnson & Johnson?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy, and a year of free analyst updates, by clicking here now.